The Food and Drug Administration on Thursday approved the first novel antipsychotic treatment in decades, a drug developed to ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Sept. 26 (UPI) -- The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. EPA must address health concerns about fluoride in water ...

young people can now locate drug dealers using their smartphones — with the relative ease of ordering food delivery or calling a ride-share service." Accidental overdoses in the U.S. have ...

Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates. Shares of the company were down 2.5% in extended trading.